exhibit_99-1.htm

*May 2008

SCOLR Pharma, Inc.

Amex: DDD

Forward-Looking Statements

§ This presentation contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995
that involve significant risks and uncertainties. These statements
represent management’s present expectations of future events
and are subject to a number of important factors that could cause
actual results to differ materially from those described in the
forward-looking statements.

§ Please refer to the risk factors and other cautionary language
included in our reports and other filings with the Securities and
Exchange Commission and available on our website.

§ We assume no obligation to update these forward-looking
statements.

*May 2008

SCOLR Pharma, Inc.

Amex: DDD

*Kalorama Information 2007 (Cited by In-Pharma
Technologist.com 1-17-2007

SCOLR Pharma: A Differentiated Oral Drug Delivery
Company

§ Proprietary, validated technology - CDT® platform

§ Greater extended-release flexibility

§ Enhanced bioavailability

§ Less complex/cost-effective formulations

§ Develops, licenses and commercializes novel products with
significant market potential

§ Distributed risk pipeline of internal and partnered targets with
significant market potential

§ Significant partnerships include

§ Dr. Reddy’s

§ BioCryst Pharmaceuticals

§ Perrigo

§ Market is forecast to increase 48% to reach $52.1 billion in
revenues by 2010*

*May 2008

SCOLR Pharma, Inc.

Amex: DDD

CDT® - A Better Oral Drug Delivery Alternative

§ New generation of less complex, cost-effective tablet/capsule
formulations

§ Uses standard GRAS ingredients and equipment

§ Based on a portfolio of 5 recently issued and pending patents for

§ Robust, predictable and programmable extended-release

§ Improved solubility/absorption/permeability/consistency

§ Gastro-intestinal (GI) stable formulations

§ Applicable to broad range of drug types and classes and consumer
products

§ 18 validating clinical studies, n > 550

§ Successful commercialization/scale-up > 250 million tablets shipped

*May 2008

SCOLR Pharma, Inc.

Amex: DDD

Important Current Collaborations Expand Pipeline
Potential

§ Dr. Reddy’s Laboratory (DRL) - Collaboration & License Agreement

§ Develop/commercialize CDT-based cardiopulmonary drug

§ BioCryst Pharmaceuticals - Research Collaboration

§ Develop an oral formulation of Peramivir, an injectible drug
currently under development by BioCryst for the treatment of
seasonal and life threatening influenza, including the avian flu

§ Perrigo Company- Development and Distribution Alliance

§ 5 CDT-based nutraceutical products currently on the market

§ Largest provider of store brand nutritional and over-the-counter
(OTC) pharmaceutical products in the U.S.

§ Global Consumer Products Company - Collaboration Extended 12/07

§ Novel application of SCOLR technology for existing global
consumer product

*May 2008

SCOLR Pharma, Inc.

Amex: DDD

	SCOLR (CDT®)	Alza (OROS®)	Biovail (FUZE®)	Flamel (Micropump®)	Pacira Former Skyepharma (GeoMatrix®)	Labopharm (Contramid®)
Wide Range of Drugs Tested	Yes (Over 40)	Yes	No	Yes	Yes	No
Mode of Action	Hydrophilic matrix, swellable polymer matrix	Reservoir device, osmotic pump	Multi-particulate, erosion, dissolution	Multi- particulate, erosion, dissolution	Multi-layered tablet, hydrophilic matrix, swellable polymer matrix	Hydrophilic matrix, swellable polymer matrix
Estimated Manufacturing Steps	2-3	18 or more	36 or more	Numerous for micro-bead	12 or more	Numerous for polymer 3-4, tablet
Limitations* *As compared with SCOLR’s CDT Matrix Technology		Complex, payload restrictions, fragile, short exclusivity	Multiple manufacturing steps, complex processes	Multiple manufacturing steps, complex processes	Specialized manufacturing equipment, complex	Special engineered polymer, limited source, availability and application

CDT Difference: Broadly Applicable, Flexible, Cost-Effective Sustained Release

*May 2008

SCOLR Pharma, Inc.

Amex: DDD

	SCOLR (CDT®)	Elan (Nanocrystal)	Nano/Micron Milling	Cydex (Inclusion complex)	Altair (Ti Nanosphere)	Solid Dispersion
Process Description	Hydrophilic matrix, swellable polymer matrix	Super critical fluid process, re- formation of nanometer sized drug crystals	Mill the drug down to the sub- micron size in order to increase surface area for enhanced solubility	Cyclodextrin inclusion complex. “Mask” the insoluble drug by incorporating into a soluble sugar ring	Engineered nano sphere. Drug is applied onto the surface, or inside	Suspend drug into inert/soluble matrix in order to prevent agglomeration during hydration
Estimated Level of Complexity	Low	High	High	High	High	Medium
Comments	Simple granulation, can be incorporated into tablets or capsules	Complex, specialized equipment, further formulation required to delivery orally and prevent agglomeration	Complex, specialized equipment, further formulation required to delivery orally and prevent agglomeration	Complex, specialized equipment, further formulation required to delivery orally and prevent agglomeration	Complex, specialized equipment, further formulation required to delivery orally and prevent agglomeration	Used alone or in combination. Often needed to prevent agglomeration

CDT Difference: Less Complex Solubility/Absorption Enhancement

*May 2008

SCOLR Pharma, Inc.

Amex: DDD

OTC Targets	Indication	Status			Comments
OTC Targets	Indication	Pre-clinical	Phase I/II	Phase III	Comments
12 hr. CDT® - Ibuprofen	Analgesia				2 Pivotal - Phase III trials completed. 3rd Pivotal - Phase III trial planned 2008. Additional use and label studies pending FDA guidance.
12 hr. CDT® - Pseudoephedrine	Cough/Cold				ANDA Submission planned in second half of 2008
Rx Targets
Raloxifene - IR	Osteoporosis				Two pilot trials completed, Pivotal trial requirements being evaluated
Ondansetron - 24 hour	Chemo-induced nausea, vomiting				Two pilot trials completed, Pivotal trial requirements being evaluated
Risperidone - 24 hour	Schizophrenia, bipolar mania				Pilot formulation work completed, trials pending financing
Rivastigmine - 24 hour	Alzheimer’s Disease				Pilot formulation work completed, trials pending financing
Peramivir (BioCryst) - IR		Influenza			Animal evaluations completed. Next stage of collaboration pending
Cardiopulmonary Drug (Dr. Reddy’s)

Confidential

Growing OTC & Rx Pipeline with Market > $15 B

*May 2008

SCOLR Pharma, Inc.

Amex: DDD

CDT® Dietary Supplements Extended-Release	Indication	Status			Comments
CDT® Dietary Supplements Extended-Release	Indication	Formulation	Scale-Up	Marketed	Comments
Glucosamine - Chondroitin	Nutritional Supplement				Introduced, Q-1, 2006
Glucosamine - Chondroitin - MSM	Nutritional Supplement				Introduced, Q-4, 2006
Glucosamine Complex	Nutritional Supplement				Introduced, Q-4, 2006
Glucosamine - Chondroitin (Low Sodium)	Nutritional Supplement				Introduced, Q-4, 2006
Calcium w/ Vitamin D	Nutritional Supplement				Introduced, Q-2, 2007
Niacin	Nutritional Supplement				Licensed, Q-1, 2008
Other(s)	Nutritional Supplement
Consumer Products
Undisclosed Application	Confidential				Formulation development and evaluation in progress

Confidential

Consumer Product Pipeline with Markets > $ 2 B

*May 2008

SCOLR Pharma, Inc.

Amex: DDD

Innovation: Better Than Brand!

5 Current Extended-Release Products …

§ Sodium Free, Glucosamine Sulfate;
Glucosamine/Chondroitin & Glucosamine
Chondroitin/MSM, Calcium w/ Vit. D:

§ Convenient - once/day

§ Active ingredients delivered over extended
time period

§ Exclusive and patented

CDT-Nutritional Products With Perrigo

*May 2008

SCOLR Pharma, Inc.

Amex: DDD

Platform Consists of Recently Issued CDT® Patents

§ 2000 / US Patent # 6,090,411

§ “Salt Patent” allows for simple two step processing. Uses ionic
interactions to correct for the limitations in other first generation
matrix based systems

§ 2002 / US Patent # 6,337,091

§ “Dual Polymer Patent” allows for simple production of tablets or
capsules. Uses ionic and anionic polymers to correct for limitations
in other biphasic/triphasic systems

§ 2003/2005/2007 US Patents # 6,517,868, # 6,936,275 and # 7,229,642

§ “Amino Acids Patent” allows for simple production of tablets. Uses
hydrophobic/polar interactions to facilitate solubility and potentially
permeability

§ 2004/ beyond

§ Additional patent filings and continuations in process

*May 2008

SCOLR Pharma, Inc.

Amex: DDD

Lead Products	Application	Potential Advantages	Status	Current Market Estimate(1)
CDT - 12 hour Ibuprofen	OTC Analgesic	- 1st extended-release OTC ibuprofen - 1 tablet vs. 3 every 12 hrs. - Lower cost - Patent protected	- Reacquired rights - Multiple pilot trials completed - 2 Pivotal trials completed - 3rd Pivotal trial planned in 2008 - Use and label studies pending further FDA guidance - NDA 505(B)2 planned	$ 8.0 billion (Global OTC analgesic)
CDT - 12 hour Pseudoephedrine	OTC Decongestant	- 1/3rd size of current OTC products - Lower cost - Patent protected	- ANDA trials completed - ANDA submission planned for later half of 2008	$ 1.0 billion (combined global market)

Notes: (1) Market Data Sources - IMS, Data Monitor, industry analysts, company disclosures, SCOLR estimates.

Current OTC Development Targets
$9 billion Combined Market(1)

*May 2008

SCOLR Pharma, Inc.

Amex: DDD

Rx products for size reference
only

6 tabs/24 hr

2 tabs/24 hr

Not Available in US

SCOLR CDT-Ibuprofen: First 12-hour Extended-Release
Tablets

CDT tablets compared to existing immediate-release tablets

*May 2008

SCOLR Pharma, Inc.

Amex: DDD

as reported by AAI
Pharma, Inc. Contract
Clinical Research

12hr CDT- Ibuprofen bioequivalent to 3 IR Tablets

§ Pivotal Clinical results - “SCOLR test formulation can be clinically substituted with the reference listed
drug.”

*May 2008

SCOLR Pharma, Inc.

Amex: DDD

N=26 subjects

as reported by
AAIPharma

CDT-Pseudoephedrine: Offers Same Drug Load with
Smaller, More Cost-Effective Tablets

Initial CDT-Pseudoephedrine testing bioequivalent to Sudafed® 12 hour (Reference
Product)

*May 2008

SCOLR Pharma, Inc.

Amex: DDD

Lead Products	Application	Potential Advantages	Status	Current Market Estimate(1)
CDT - IR Raloxifene	Rx Osteoporosis	- Less drug for similar results(2) - Simplified manufacturing - Lower cost - Patent protected	- 2 Human studies completed - Results positive - Reviewing clinical requirements for regulatory approval with FDA	$ 1.0 billion (Global)
CDT - 24 hour Ondansetron	Rx Anti-Nausea	- 1 tablet vs. 3 every 24 hrs. - Simplified manufacturing - Lower cost - Patent Protected	- 2 Human studies completed - Results Positive - Reviewing clinical requirements for regulatory approval with FDA	$ 1.6 billion (Global)
BioCryst Collaboration: CDT - Neuraminidase Inhibitor (Peramivir)	Rx Flu Treatment	-Convert current injectible product to oral tablet - Ease of administration - Consumer compliance - Broad application	- Initial animal studies completed - Evaluation in progress - Next stage of collaboration pending	> $1.0 billion (Global)
DRL Collaboration: Undisclosed CDT- based Rx target	Cardiopulmonary	- Lower cost - Patent protected - Other non-disclosed	- Initial formulation completed - Product transfer initiated -	Undisclosed

Notes: (1) Market data sources - IMS, Data Monitor, industry analysts, company disclosures, SCOLR estimates.

(2) Based on animal and clinical study results

Current Rx Development Targets
$ 3.6 billion Combined Market(1)

*May 2008

SCOLR Pharma, Inc.

Amex: DDD

Lead Products	Application	Potential Advantages	Status	Current Market Estimate(1)
CDT - 24 hour Risperidone	Rx schizophrenia and bipolar mania management	-1 tablet vs. 2 every 24 hrs. - Simplified manufacturing - Lower cost - Patent protected	-Pilot Formulation work completed -Pilot clinical trials pending financing	$ 1.8 billion (Global)
CDT - 24 hour Rivastigmine	Rx Alzheimer’s Disease	- 1 tablet vs. 2 every 24 hrs. - Improved convenience - Patent protected	- Pilot Formulation work completed -Pilot clinical trials pending financing	$ 0.5 billion (Global)
				$ 0.5 billion (Global)

Notes: (1) Market data sources - IMS, Data Monitor, industry analysts, company disclosures, SCOLR estimates.

New Rx Development Targets
$2.3 billion Combined Market(1)

*May 2008

SCOLR Pharma, Inc.

Amex: DDD

2008 Strategic Growth Initiatives

§ Complete pivotal trials and label comprehension study
for 12 hour CDT-Ibuprofen NDA 505(b)2 submission

§ Submit ANDA for 12 hour CDT-Pseudoephedrine

§ Expand “All Day” product suite with Perrigo

§ Advance existing portfolio targets

§ Apply CDT platform to new targets

§ Enter new alliance and partnership agreements

§ Build intellectual property estate/portfolio

§ Complete $4.1 million lease buyout

*May 2008

SCOLR Pharma, Inc.

Amex: DDD

Management

§ Daniel O. Wilds, President, CEO and Director, appointed 2003

§ Previously, Chairman, President and CEO of Northwest Biotherapeutics,
President and CEO of Shiloov Biotechnologies (USA), Adeza Biomedical and
Medisense, President of Baxter’s Chemotherapy Service, and President and
COO of Travenol-Genetech, a joint venture between Baxter International and
Genentech

§ Alan M. Mitchel, Sr. VP Business & Legal Affairs and CLO, appointed 2005

§ Extensive legal, business and corporate finance experience most recently at
Gray Cary, Former outside counsel for SCOLR

§ Stephen J. Turner, VP Research and Development, CTO, appointed 2003

§ Employed in positions of increasing responsibility at SCOLR since 1999. Built
SCOLR’s R&D and Information Technology Functions

§ Richard M. Levy, CPA, VP of Finance, CFO, appointed 2006

§ Previously Corporate Controller for Safeco Insurance, CFO for the Specialty
Finance Segment and Corporate Controller for Washington Mutual Bank,
Senior Vice President and Controller of Texas operations at Bank of America

§ Tanya M. Raco, Assoc. VP of Regulatory and Quality Affairs, appointed 2006

§ Employed in positions of increasing responsibility at SCOLR since 1997. Built
SCOLR’s Regulatory and Quality Assurance Functions

*May 2008

SCOLR Pharma, Inc.

Amex: DDD

Balance Sheet and Capital Structure

Balance Sheet Data

March 31, 2008 (In Thousands)

Cash and cash equivalents $ 9,500

Settlement from lease buyout (April, 2008) 4,100

Total $13,600

Working Capital $9,500

Total Assets 11,300

Total Debt 171

(In Millions)

Common Shares Outstanding 41.1

Fully - Diluted Shares 48.4

*May 2008

SCOLR Pharma, Inc.

Amex: DDD

SCOLR Pharma
Well Positioned for the Future

§ Large, growing markets

§ Unique, broadly applicable, patented technology platform
with important benefits

§ Expanding prescription and OTC pipeline with multiple
clinical and pre-clinical candidates

§ Royalty revenues from existing products

§ Value driving milestones

§ Experienced management team